Real world trial confirms SGLT-2 inhibitors’ renal benefit
The large study found a marked effect in reducing serious kidney events, researchers say
Patients with type 2 diabetes prescribed SGLT-2 inhibitors reduce their risk of serious renal events by nearly 60% compared with those on DPP-4 inhibitors, a large cohort study has found.
The ‘real world’ finding suggest that even those patients without overt cardiovascular or chronic kidney disease can benefit, the Scandinavian researchers say.
